ERR2208973
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.300
- SPERMATOGENESIS+0.300
- E2F_TARGETS+0.200
- INTERFERON_GAMMA_RESPONSE+0.200
- MYC_TARGETS_V1+0.200
- ANDROGEN_RESPONSE+0.100
- COMPLEMENT+0.100
- G2M_CHECKPOINT+0.100
- INTERFERON_ALPHA_RESPONSE+0.100
- KRAS_SIGNALING_DN+0.100
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- NOTCH_SIGNALING-0.500
- ANGIOGENESIS-0.400
- TGF_BETA_SIGNALING-0.400
- APICAL_JUNCTION-0.300
- HEDGEHOG_SIGNALING-0.300
- WNT_BETA_CATENIN_SIGNALING-0.300
- ADIPOGENESIS-0.200
- APOPTOSIS-0.200
- COAGULATION-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR10899995 | — | — | 0.804 |
| 2 | MBCProject_1542_T2_RNA | — | D | 0.784 |
| 3 | c94686d5.355c.432f.bc98.ccdd30a209de | — | cohortA4 | 0.782 |
| 4 | 90c9f8cd-4c8c-4f07-af2f-e17db69bd561 | — | — | 0.770 |
| 5 | s0122212 | — | — | 0.761 |
| 6 | SRR2016949 | — | — | 0.758 |
| 7 | SRR12202426 | — | — | 0.745 |
| 8 | SRR12202422 | — | — | 0.743 |
| 9 | SRR1313162 | — | C | 0.743 |
| 10 | SRR25617825 | — | C | 0.741 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.300 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.200 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.100 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.100 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.100 | Remibrutinib | — uncovered |